Advances in the understanding of Acute Myeloid Leukaemia (AML) cell biology in recent years have unleashed a wave of new product development and treatment options available to patients.
This market evolution will continue to accelerate, with dozens of Phase 3 trials in progress addressing both adult and childhood AML treatment needs.
Capitalizing on our unique expertise in the AML market and in patient chart-based research, AMLsyndiTrackTM, our AML syndicated study uses real-world data to monitor the evolution of AML management.
Example of recent release:- Data from Jan21 in FR, UK, DE, ES, IT, BE, CH, AT, CA
- 398 Onco-Hematologists
- 2,773 real-world patient charts analyzed